Cargando…

Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy

BACKGROUND: Magnetic resonance imaging (MRI) has been proposed to guide breast cancer surgery by measuring residual tumour after neoadjuvant chemotherapy. This study-level meta-analysis examines MRI's agreement with pathology, compares MRI with alternative tests and investigates consistency bet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marinovich, M L, Macaskill, P, Irwig, L, Sardanelli, F, von Minckwitz, G, Mamounas, E, Brennan, M, Ciatto, S, Houssami, N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776985/ https://www.ncbi.nlm.nih.gov/pubmed/23963140 http://dx.doi.org/10.1038/bjc.2013.473

Ejemplares similares

Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis
por: Marinovich, Michael L., et al.
Publicado: (2015)

Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer
por: Al-Hattali, Samia, et al.
Publicado: (2019)

Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients
por: Bouzón, Alberto, et al.
Publicado: (2016)

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques
por: Heil, Joerg, et al.
Publicado: (2015)

State of the art in neoadjuvant therapy of breast cancer
por: Minckwitz, Gunter von, et al.
Publicado: (2013)

Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
por: Gunia, Sommer R., et al.
Publicado: (2012)

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Baron, Paul, et al.
Publicado: (2015)

Higher underestimation of tumour size post-neoadjuvant chemotherapy with breast magnetic resonance imaging (MRI)—A concordance comparison cohort analysis
por: Wu, Wen-Pei, et al.
Publicado: (2019)

Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response
por: Stevens, William, et al.
Publicado: (2021)

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
por: Guo, Sanxing, et al.
Publicado: (2020)

New technologies in screening for breast cancer: a systematic review of their accuracy
por: Irwig, L, et al.
Publicado: (2004)

Recent advances in systemic therapy. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agents
por: Untch, Michael, et al.
Publicado: (2009)

Correction: Higher underestimation of tumour size post-neoadjuvant chemotherapy with breast magnetic resonance imaging (MRI)—A concordance comparison cohort analysis
Publicado: (2020)

Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3)
por: Houssami, N, et al.
Publicado: (2007)

Neoadjuvant nab-paclitaxel in the treatment of breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2016)

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients
por: Miquel-Cases, Anna, et al.
Publicado: (2016)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

Surgical management of the breast and axilla after neoadjuvant treatment: the role of sentinel node biopsy
por: Mamounas, EP
Publicado: (2009)

Predicting pathologic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer using multiparametric MRI
por: Lu, Nannan, et al.
Publicado: (2021)

Efficacy Evaluation of Neoadjuvant Chemotherapy in Breast Cancer by MRI
por: Liu, Yongguang, et al.
Publicado: (2022)

MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer
por: Goorts, Briete, et al.
Publicado: (2018)

Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
por: Hu, Shen-Bao, et al.
Publicado: (2019)

Neoadjuvant chemotherapy and pathologic response: a retrospective cohort
por: de Andrade, Diocésio Alves Pinto, et al.
Publicado: (2013)

A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis
por: Li, Tong, et al.
Publicado: (2023)

Relationship between tumour size and response to neoadjuvant chemotherapy among breast cancer patients in a tertiary center in Nigeria
por: Samuel, Olatoke, et al.
Publicado: (2018)

Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
por: Braman, Nathaniel M., et al.
Publicado: (2017)

The Tumor–Fat Interface Volume of Breast Cancer on Pretreatment MRI Is Associated with a Pathologic Response to Neoadjuvant Chemotherapy
por: Cho, Hwan-ho, et al.
Publicado: (2020)

The Diagnostic Performance of DCE-MRI in Evaluating the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis
por: Cheng, Qingqing, et al.
Publicado: (2020)

A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy
por: Sutton, Elizabeth J., et al.
Publicado: (2020)

Rates of reoperation after breast conserving cancer surgery in Western Australia before and after publication of the SSO-ASTRO margins guideline
por: Marinovich, M. Luke, et al.
Publicado: (2023)

Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma
por: Moore, Jonathan L., et al.
Publicado: (2023)

Second breast cancers in a Tuscan case series: characteristics, prognosis, and predictors of survival
por: Ciatto, S, et al.
Publicado: (2008)

Pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: Perfusion metrics of dynamic contrast enhanced MRI
por: Lee, Jeongmin, et al.
Publicado: (2018)

Erratum to: Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI
por: Braman, Nathaniel M., et al.
Publicado: (2017)

Direct comparison of PET/CT and MRI to predict the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis
por: Chen, Lihua, et al.
Publicado: (2017)

Radiomics of MRI for the Prediction of the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Single Referral Centre Analysis
por: Pesapane, Filippo, et al.
Publicado: (2021)

Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis
por: Winfield, Jessica M., et al.
Publicado: (2021)

Agreement between dynamic contrast-enhanced magnetic resonance imaging and pathologic tumour size of breast cancer and analysis of the correlation with BI-RADS descriptors
por: Gemici, Aysegul Akdogan, et al.
Publicado: (2019)

Screening outcomes by risk factor and age: evidence from BreastScreen WA for discussions of risk‐stratified population screening
por: Noguchi, Naomi, et al.
Publicado: (2021)

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma
por: Jones, R L, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_qgp3109tbc1djrtfioriuv7re5